Leaptx.com

Leaptx.com has Server used 185.230.63.186 IP Address with Hostname in . Below listing website ranking, Similar Webs, Backlinks. This domain was first 2015-10-15 (5 years, 245 days) and hosted in , server ping response time 31 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Leaptx keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Leaptx
2 Leaptx stock
3 Leapt meaning
4 Leapt or leaped
5 Leaptv disney pixar pals
6 Leapt xword
7 Leapty
8 Leaptv
9 Leapto

Hosting Provider

Website: Leaptx.com
Hostname: 185.230.63.186
Country:
Latitude:
Longitude:
Area Code:
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Funeralhomesguide.com (7 seconds ago)

   » Connx.com (1 seconds ago)

   » Since1917.com (2 seconds ago)

   » Paperity.org (5 seconds ago)

   » Gmcrcanadaordering.com (4 seconds ago)

   » Braider.com (3 seconds ago)

   » Eptingevents.com (3 seconds ago)

   » Vutienit.com (1 seconds ago)

   » Esbyn.com (32 seconds ago)

Results For Websites Listing

Found 43 Websites with content related to this domain, It is result after search with search engine

LPTX Stock Price Leap Therapeutics Inc. Stock Quote (U.S

Marketwatch.com   DA: 19 PA: 21 MOZ Rank: 40

  • LPTX | Complete Leap Therapeutics Inc
  • View real-time stock prices and stock quotes for a full financial overview.

Leap Therapeutics To Present At Raymond James 2021 Virtual

Homenewshere.com   DA: 16 PA: 50 MOZ Rank: 67

  • 2 days ago · Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

#LEAP Texas Association Of American Colleges & Universities

Aacu.org   DA: 12 PA: 29 MOZ Rank: 43

LEAP Texas joined the Faculty Collaboratives in 2014, shortly after the state adopted six new core objectives that drive the Texas Core Curriculum.

Leap Therapeutics Inc (LPTX) Quote

Morningstar.com   DA: 19 PA: 23 MOZ Rank: 45

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the

Leap Therapeutics Reports First Quarter 2021 Financial

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 68

Leap Therapeutics Announces Changes To Virtual Format And

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 69

Leap Therapeutics, Inc. (LPTX) Stock Price Today, Quote

Seekingalpha.com   DA: 16 PA: 12 MOZ Rank: 34

  • A high-level overview of Leap Therapeutics, Inc
  • Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Leap Therapeutics Announces FDA Fast Track Designation

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 75

Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

LPTX Stock Forecast, Price & News (Leap Therapeutics)

Marketbeat.com   DA: 18 PA: 20 MOZ Rank: 46

  • 4 brokers have issued twelve-month price objectives for Leap Therapeutics' stock
  • Their forecasts range from $3.50 to $8.00
  • On average, they anticipate Leap Therapeutics' share price to reach $4.88 in the next twelve months
  • This suggests a possible upside of 170.8% from the stock's current price
  • View analysts' price targets for Leap

LPTX:NASDAQ GM Stock Quote

Bloomberg.com   DA: 17 PA: 14 MOZ Rank: 40

Stock analysis for Leap Therapeutics Inc (LPTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Leap Therapeutics LinkedIn

Linkedin.com   DA: 16 PA: 26 MOZ Rank: 52

  • Leap Therapeutics | 1,036 followers on LinkedIn
  • Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of

Leap Therapeutics To Present At Raymond James 2021 Virtual

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 88

2 days ago · For more information about Leap Therapeutics, visit https://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at https://www.sec.gov or via https://investors

Leap Therapeutics To Present At Raymond James 2021 Virtual

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 74

  • 2 days ago · CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc
  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E
  • Onsi, President and Chief Executive Officer, will present a corporate overview at the Raymond James 2021 Virtual Human Health Innovation Conference on …

Leap Therapeutics To Present At Raymond James 2021 Virtual

Biospace.com   DA: 16 PA: 50 MOZ Rank: 79

  • CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E
  • Onsi, President and Chief Executive Officer, will present a corporate overview at the Raymond James 2021 Virtual Human Health Innovation Conference on Monday, June 21, 2021 …

Leap Therapeutics And Flagship Biosciences Develop Image

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 76

  • Heather Savelle Investor Relations Argot Partners 212-600-1902 [email protected]
  • Media Contact for Leap Therapeutics: David Rosen Argot Partners 212-600-1902 [email protected]
  • For Flagship Biosciences: Pamela Curran, Principal Stratos Global Marketing 303-818-9316 [email protected]

Leap Therapeutics, Inc. 2020 Annual Meeting

Cstproxy.com   DA: 16 PA: 13 MOZ Rank: 44

  • Print Entire Document Print 2020 Annual Meeting Click here to download a printable version of this entire document
  • After the document downloads, …

Leap Therapeutics To Present At 39th Annual J.P. Morgan

Wfmz.com   DA: 12 PA: 50 MOZ Rank: 78

  • 4, 2021 /PRNewswire/ -- Leap Therapeutics, Inc
  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that

Leap Therapeutics To Present At Stifel 2020 Healthcare

Bloomberg.com   DA: 17 PA: 50 MOZ Rank: 84

  • Onsi President & Chief Executive Officer Leap Therapeutics, Inc
  • 617-714-0360 [email protected]leaptx.com Heather Savelle Investor …

Leap Therapeutics To Present At H.C. Wainwright 22nd

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 86

  • Leap Therapeutics to Present at H.C
  • Wainwright 22nd Annual Global Investment Conference
  • 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc
  • (Nasdaq: LPTX ), a biotechnology

Leap Therapeutics To Present At Upcoming Virtual Investor

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 96

    Will The Rally Continue

    Drpgazette.com   DA: 14 PA: 50 MOZ Rank: 84

    • Leap Therapeutics Inc (NASDAQ:LPTX) is trading up in the pre-market session on Thursday
    • The stock has been witnessing solid rally over the past month with a jump 15%
    • Market Reaction As of 7:47, LPTX is up by 3.89% to $1.87 with 1.4K shares traded hands
    • Major Trigger: Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference Key …

    Leap Therapeutics To Present Esophagogastric Cancer Data

    Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 88

    • Heather Savelle Investor Relations Argot Partners 212-600-1902 [email protected]
    • Leap Therapeutics logo (PRNewsfoto/LEAP Therapeutics) Cision.

    Leap Therapeutics To Present At H.C. Wainwright 22nd

    Wfmz.com   DA: 12 PA: 50 MOZ Rank: 84

    • 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc
    • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that

    MDKN-01, A Novel Anti-DKK1 Monoclonal Antibody, Enhances

    Pubmed.ncbi.nlm.nih.gov   DA: 23 PA: 10 MOZ Rank: 56

    • 4 Translational Biology, Leap Therapeutics [email protected]leaptx.com
    • 5 Pathology, Athenaeum Pathology Consulting, LLC
    • PMID: 33443105 DOI: 10.1158/1541-7786.MCR-20-0799 Abstract Dickkopf-1 (DKK1), a secreted modulator of Wnt signaling, is overexpressed in many cancers, is often associated with worse clinical outcomes, and has been shown to have

    Leap Therapeutics To Present At Upcoming Virtual Investor

    Eresearch.fidelity.com   DA: 22 PA: 45 MOZ Rank: 91

    • Onsi President & Chief Executive Officer Leap Therapeutics, Inc
    • (LPTX) 617-714-0360 [email protected]leaptx.com
    • Heather Savelle Investor Relations Argot Partners 212-600-1902 [email protected]

    Leap Therapeutics Presents Non-clinical And Phase 1 Data

    Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 96

    Leap Therapeutics To Present At The 2018 JMP Securities

    Globenewswire.com   DA: 21 PA: 50 MOZ Rank: 97

    Leap Therapeutics Presents DKN-01 Clinical Data At The

    Streetinsider.com   DA: 21 PA: 50 MOZ Rank: 98

    Leap Therapeutics To Participate At Piper Sandler 32nd

    Benzinga.com   DA: 16 PA: 50 MOZ Rank: 94

    Company Overview April 2019

    Static.seekingalpha.com   DA: 23 PA: 48 MOZ Rank: 100

    www.leaptx.com Patient initiated on combo with paclitaxel, discontinued paclitaxel end of cycle 2 DKN-01 monotherapy for 16 cycles; best response of 72% reduction in tumor volume

    Leap Therapeutics To Present At Cowen 40th Annual Health

    Benzinga.com   DA: 16 PA: 50 MOZ Rank: 96

    • 26, 2020 /PRNewswire/ -- Leap Therapeutics, Inc
    • (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology

    Leap Therapeutics Presents DKN-01 Clinical Data At The

    Stocktitan.net   DA: 18 PA: 50 MOZ Rank: 99

    • Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics
    • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein
    • DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

    Recently Analyzed Sites

    Funeralhomesguide.com (7 seconds ago)

    Connx.com (1 seconds ago)

    Since1917.com (2 seconds ago)

    Paperity.org (5 seconds ago)

    Gmcrcanadaordering.com (4 seconds ago)

    Braider.com (3 seconds ago)

    Eptingevents.com (3 seconds ago)

    Vutienit.com (1 seconds ago)

    Esbyn.com (32 seconds ago)

    1515hh.com (11 seconds ago)

    Kcls.org (26 seconds ago)

    Dmpchicago.com (21 seconds ago)

    Medicalhair4u.com (4 seconds ago)

    Sxtfgg.com (8 seconds ago)

    Leaptx.com (0 seconds ago)

    Crypto-gambling.net (3 seconds ago)

    Bolagila.net (8 seconds ago)